ESMO

Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors. Read More ›

Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers. Read More ›

Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients. Read More ›

Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies. Read More ›

Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation. Read More ›

Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens. Read More ›

Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer. Read More ›

The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile. Read More ›

Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support. Read More ›